Stoke Therapeutics (STOK) Total Current Liabilities (2018 - 2026)

Stoke Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $40.8 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 8.68% year-over-year to $40.8 million; the TTM figure through Mar 2026 stood at $40.8 million (down 8.68% YoY), while the FY2025 annual figure was $57.9 million, up 44.49% from the prior year.
• Total Current Liabilities was $40.8 million for Q1 2026 at Stoke Therapeutics, down from $57.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $57.9 million in Q4 2025 to a low of $21.8 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $36.1 million across 5 years, with a median of $35.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 274.88% in 2022, then retreated 21.02% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $31.4 million in 2022, then retreated by 1.83% to $30.8 million in 2023, then advanced by 29.97% to $40.1 million in 2024, then jumped by 44.49% to $57.9 million in 2025, then declined by 29.49% to $40.8 million in 2026.
• The last three Total Current Liabilities figures came in at $40.8 million (Q1 2026), $57.9 million (Q4 2025), and $41.7 million (Q3 2025), per Business Quant data.